安瑞克芬注射液 | China Drugs ListAnrikefon injection | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 企业
- 海思科医药集团股份有限公司Haisco Pharmaceutical Group Co., Ltd.
- 药品类型
- 化学药Chemical medicine
- 治疗领域
- 麻醉与疼痛Anesthesia & pain
- 公开来源记录的适应症
- ①用于治疗腹部手术后的轻、中度疼痛；说明书给出成人用药方案，尚无18岁以下患者临床研究资料。②用于维持性血液透析的慢性肾脏疾病相关中重度瘙痒成人患者。1. Treatment of mild-to-moderate pain after abdominal surgery. The prescribing information provides an adult regimen; clinical study data in patients under 18 years of age are not available. 2. Treatment of moderate-to-severe chronic kidney disease-associated pruritus in adults receiving maintenance hemodialysis.
- 适应症来源与口径
- 来源日期： 2025-05-13, 2026-06, 2026-10-23. 生产商面向中国大陆的药品说明书。 批准或修订日期为空或为占位值；尚未确认准确修订日期。 证据核查日期：2026年10月23日。Source date(s): 2025-05-13, 2026-06, 2026-10-23. Manufacturer prescribing information for Mainland China. An approval or revision date is blank or a placeholder; the exact revision date is not confirmed. Evidence review: 23 October 2026.
- 说明书信息局限
- 已取得完整官方药品说明书。 中国大陆说明书。Complete official prescribing information obtained. Mainland China label.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 待逐一核查各市场。Market-by-market verification pending.
- 医保分类
- 已纳入国家医保（乙类）Included in national insurance (Category B)
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保限制
- 限腹部手术后的轻、中度疼痛。Limited to mild-to-moderate pain after abdominal surgery.
- 医保期限
- 2026-01-01 至 2027-12-312026-01-01 to 2027-12-31
- 医保核查说明
- 按成分／剂型名称精确或标准化匹配。报销仍取决于剂型及目录所列支付限制。Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.